

William Bains

Short CV

William was educated in London, and at Oxford where he gained a 1st in biochemistry. After a PhD at Warwick and Postdoc at Stanford, California, William held a lectureship at University of Bath, researching *inter alia* genomics and bioinformatics technologies and what is now called 'functional genomics'. In 1988 he joined a technology consultancy, developing new life-science based technologies such as Sequencing by Hybridization (which he co-invented), and evaluating new technology opportunities in biotech. and pharmaceuticals. In October 1996 he joined Merlin Ventures, a specialist bioscience investment group, to head the science team co-founding and funding new bioscience companies in the UK. William wrote most of the first round business plans for Cyclacel, Eurogene (now Ark Therapeutics), Microscience.

In 1999 William founded Amedis Pharmaceuticals Ltd, developing new medicines from the application of organosilicon chemistry to drug discovery. William created the concept and the company, and took it from concept through three funding rounds to an established company with a strong management team, two technology platforms, a major Pharmaceutical collaboration and exciting product development programmes.

In 2002 William Founded Delta G Ltd., a company exploring a 'systems biology' approach to diseases of energy metabolism, and in 2003 he co-founded Choracle Ltd. with David Melvin and Antranig Basman, to provide software prediction of toxicity for medicine and chemicals development. He also runs a consulting company, Rufus Scientific, providing advice on identifying and exploiting genuinely breakthrough science and technology, and teaches at Cambridge University

William's expertise has been recognised with Toshiba Year of Invention prize in 1992, election to Human Genome Organisation in 1994, and appointment as a visiting Professor at Imperial College, London in 1999. He is author of numerous papers, patents, and three books.